Skip to main content
Premium Trial:

Request an Annual Quote

RXi Q2 Losses Hold Steady

Premium

NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week reported its financial results for the second quarter, posting an unchanged net loss as expenses largely held steady from last year.

The company's loss of the three-month period ended June 30 was $2 million, the same as the year before. Research and development spending held steady at $1.2 million, while general and administrative costs edged up $100,000 to $1 million.

At the end of the quarter, RXi had cash and cash equivalents of roughly $11.9 million.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.